MediPal Holdings Corporation
MEPDFOTCHealthcare● Active
$18.35
+$0.00(+0.00%)
Market Cap$3.8B
P/E Ratio—
52W High$19
52W Low$15.9
MediPal Holdings Corporation (MEPDF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MEPDF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
$0.16
Est. $0.24 · -34.1%
Revenue
$5.70B
Est. $5.62B · +1.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
MEPDF reports quarterly as a OTC-listed Medical - Distribution company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 24, 2026 | — | — | — | — | $6.07B | — |
| ▼ Q2 FY2026 | May 14, 2026 | $0.24 | $0.16 | -34.1% | $5.70B | $5.62B | +1.5% |
| ▲ Q1 FY2026 | Feb 9, 2026 | $0.32 | $0.48 | +48.3% | $6.47B | $6.45B | +0.3% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.26 | $0.41 | +57.7% | $6.44B | $6.57B | -2.0% |
| — Q3 FY2025 | Aug 5, 2025 | $0.32 | $0.32 | -0.6% | $6.53B | $6.37B | +2.4% |
| ▲ Q2 FY2025 | May 12, 2025 | $0.11 | $0.13 | +17.5% | $5.94B | $6.43B | -7.6% |
| ▲ Q1 FY2025 | Feb 10, 2025 | $0.22 | $0.44 | +100.5% | $6.25B | $6.10B | +2.5% |
| ▲ Q4 FY2024 | Nov 1, 2024 | $0.37 | $0.43 | +14.8% | $6.41B | $6.35B | +1.0% |
Q3 FY2026
Jul 24, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
$0.16
EPS Est.
$0.24
EPS Surpr.
-34.1%
Revenue
$5.70B
Q1 FY2026
Feb 9, 2026Beat
EPS Actual
$0.48
EPS Est.
$0.32
EPS Surpr.
+48.3%
Revenue
$6.47B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.41
EPS Est.
$0.26
EPS Surpr.
+57.7%
Revenue
$6.44B
Q3 FY2025
Aug 5, 2025
EPS Actual
$0.32
EPS Est.
$0.32
EPS Surpr.
-0.6%
Revenue
$6.53B
Q2 FY2025
May 12, 2025Beat
EPS Actual
$0.13
EPS Est.
$0.11
EPS Surpr.
+17.5%
Revenue
$5.94B
Q1 FY2025
Feb 10, 2025Beat
EPS Actual
$0.44
EPS Est.
$0.22
EPS Surpr.
+100.5%
Revenue
$6.25B
Q4 FY2024
Nov 1, 2024Beat
EPS Actual
$0.43
EPS Est.
$0.37
EPS Surpr.
+14.8%
Revenue
$6.41B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.24 | $0.24 | $0.24 | 1 |
| Q4 FY2025 | $0.32 | $0.32 | $0.32 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $926B | $930B | $934B | 1 |
| Q4 FY2026 | $1046B | $1050B | $1054B | 1 |
| Q3 FY2026 | $979B | $985B | $991B | 2 |
| Q2 FY2026 | $970B | $972B | $973B | 2 |
| Q1 FY2026 | $895B | $898B | $902B | 3 |
| Q4 FY2025 | $1003B | $1012B | $1018B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -34.1% | $18.35 | $18.35 | +0.00% |
| ▲ Q1 FY2026 | Feb 9, 2026 | +48.3% | $19.00 | $19.00 | +0.00% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +57.7% | $16.50 | $16.50 | +0.00% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -0.6% | $15.90 | $15.90 | +0.00% |
| ▲ Q2 FY2025 | May 12, 2025 | +17.5% | $14.80 | $14.80 | +0.00% |
| ▲ Q1 FY2025 | Feb 10, 2025 | +100.5% | $13.48 | $13.48 | +0.00% |
| ▲ Q4 FY2024 | Nov 1, 2024 | +14.8% | $13.24 | $13.24 | +0.00% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -23.9% | $13.24 | $13.24 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 14, 2026
EPS Beat/Miss
-34.1%
Price Before
$18.35
Price After
$18.35
Q1 FY2026+0.00%
Report Date
Feb 9, 2026
EPS Beat/Miss
+48.3%
Price Before
$19.00
Price After
$19.00
Q4 FY2025+0.00%
Report Date
Nov 5, 2025
EPS Beat/Miss
+57.7%
Price Before
$16.50
Price After
$16.50
Q3 FY2025+0.00%
Report Date
Aug 5, 2025
EPS Beat/Miss
-0.6%
Price Before
$15.90
Price After
$15.90
Q2 FY2025+0.00%
Report Date
May 12, 2025
EPS Beat/Miss
+17.5%
Price Before
$14.80
Price After
$14.80
Q1 FY2025+0.00%
Report Date
Feb 10, 2025
EPS Beat/Miss
+100.5%
Price Before
$13.48
Price After
$13.48
Q4 FY2024+0.00%
Report Date
Nov 1, 2024
EPS Beat/Miss
+14.8%
Price Before
$13.24
Price After
$13.24
Q3 FY2024+0.00%
Report Date
Aug 1, 2024
EPS Beat/Miss
-23.9%
Price Before
$13.24
Price After
$13.24
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate6 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MEPDF ends December
MediPal Holdings Corporation (MEPDF) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $0.16 — missing the analyst consensus of $0.24 by -34.1%. The next MEPDF earnings date is expected around September 1, 2026.
Each quarter, investors track MEPDF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MEPDF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MEPDF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MEPDF earnings · 5 questionsMediPal Holdings Corporation's next earnings report is expected around September 1, 2026. MEPDF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MEPDF historically reports after market close (AMC).
MEPDF earnings datewhen is MEPDF earningsMEPDF next earnings datewhen does MEPDF report earningsMEPDF earnings calendar
▸ Source: FMP · MediPal Holdings Corporation SEC filings · US GAAP · MediPal Holdings Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026